October 26, 2017

Revisions of Consolidated Financial Forecasts

ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative Director and CEO: Gyo Sagara) announced today that it has revised its 2nd quarter consolidated financial forecasts for the fiscal year ending March 31, 2018, which were announced on May 11, 2017, in light of recent business trends.

  1. Revisions to 2nd Quarter Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2018 (April 1, 2017 - September 30, 2017)

    (Millions of yen, except Basic earnings per share)

    Revenue

    Operating profit

    Profit before tax

    Profit

    （Owners of

    the Parent Company）

    Basic earnings per share

    （yen）

    Previous Forecast (A)

    112,500

    13,200

    14,500

    10,700

    20.19

    Revised Forecast (B)

    121,000

    26,700

    28,300

    21,200

    40.61

    Change (B - A)

    8,500

    13,500

    13,800

    10,500

    -

    Change (%)

    7.6％

    102.3％

    95.2％

    98.1％

    -

    (Reference)

    Results of the previous corresponding period

    117,726

    30,135

    31,127

    23,119

    43.62

  2. Reasons for Revisions

The revenue is forecasted to be ¥121.0 billion, an increase of ¥8.5 billion from the previous forecast. The royalty income of OPDIVO® Intravenous Infusion mainly from Bristol-Myers Squibb Company is expected to exceed the previous forecasts. In addition, the sales of OPDIVO are also expected to exceed the previous forecasts although the sales of OPDIVO will be significantly decreased due to the influence of drug price cut executed in February 2017.

With respect to profit, Operating profit is forecasted to increase by ¥13.5 billion to ¥26.7 billion, Profit before tax will increase by ¥13.8 billion to 28.3 billion, Profit for the period attributable to owners of the parent company is expected to grow by ¥10.5 billion to

¥21.2 billion, from the respective previous forecasts. This revision is made because

parts of Research and development costs and Selling, general and administrative expenses expected in the 2nd quarter cumulative period will be incurred to the 3rd quarter and thereafter.

We are now scrutinizing its full year forecast and it will be presented at the time of the six months ending results announcement on November 6, 2017.

(Note) The above financial forecasts and statements contained in this announcement are made based on information available as of the announcement date. Actual results may differ materially from those set forth in the announcements due to various uncertain factors

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications public_relations@ono.co.jp

ONO Pharmaceutical Co. Ltd. published this content on 26 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 26 October 2017 06:38:06 UTC.

Original documenthttp://www.ono.co.jp/eng/news/pdf/sm_cn171026.pdf

Public permalinkhttp://www.publicnow.com/view/169E60D6D7497470B8D5E0EA1AD0FC711D1F318C